Literature DB >> 15270426

Canal wall down tympanoplasty surgery with or without ossiculoplasty in cholesteatoma: hearing results.

A Artuso1, W di Nardo, E De Corso, M R Marchese, N Quaranta.   

Abstract

Aim of the study was to evaluate the functional results, in two homogeneous groups, for severity of the disease, submitted to canal-wall-down tympanoplasty (TPL CWD), with and without ossiculoplasty. A total of 60 patients who underwent canal-wall-down tympanoplasty for cholesteatoma were evaluated: 31 underwent ossiculoplasty (group A) and 29 classic Wullstein type III and IV operation (group B). Hearing results were evaluated 2 years after surgery according to the AAO-HHS guidelines. Pre-operative audiometrics revealed an air conduction PTA (AC-PTA) of 45.12 dB in group A, and 56.25 dB in group B. Bone conduction PTA (BC-PTA) was 16.86 dB in group A and 26.06 in group B. Two years after surgery, AC-PTA was 42.98 dB in group A and 58.65 dB in group B; BCPTA was 18.79 dB in group A and 25.13 dB in group B. The mean pre-operative ABG was 28.44 dB in group A and 30.14 dB in group B. Two years after surgery, group A showed a mean ABG of 24.06 and group B of 35.54 dB, the difference between the two groups was significant (p = 0.03). In conclusion, the functional results observed in the present study support the need to reconstruct the ossicular chain in canal-wall-down tympanoplasty, in fact, ossiculoplasty is associated with a better hearing gain than the classic Wullstein operations.

Entities:  

Mesh:

Year:  2004        PMID: 15270426

Source DB:  PubMed          Journal:  Acta Otorhinolaryngol Ital        ISSN: 0392-100X            Impact factor:   2.124


  2 in total

1.  Posttraumatic cholesteatoma complicated by a facial paralysis: a case report.

Authors:  M Chihani; A Aljalil; M Touati; B Bouaity; H Ammar
Journal:  Case Rep Otolaryngol       Date:  2012-02-09

2.  Ossicular chain lesions in cholesteatoma.

Authors:  R Albera; A Canale; E Piumetto; M Lacilla; F Dagna
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-10       Impact factor: 2.124

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.